Search Results

You are looking at 1 - 10 of 11 items for :

  • "Capecitabine" x
  • Refine by Access: Content accessible to me x
Clear All

Summary

Five new peaks of potential impurities, ranging from 0.05 to 0.12% on an area-percent basis, have been observed in reversed-phase high-performance liquid chromatography of capecitabine drug substance. On the basis of comparison of relative retention times and mass values two of the impurities were identified as intermediates in the process used for synthesis of capecitabine and were characterized as (2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyltetrahydrofuran-3,4-diyl diacetate and 2-(5-fluoro-2-oxo-4-(pentyloxycarbonylamino)pyrimidin-1(2H)-yl)-5-methyl tetrahydrofuran-3,4-diyl diacetate. The area percentages of two of the other peaks increased substantially when the drug was treated with acid and base. The three compounds other than the two intermediates were isolated by preparative HPLC with gradient elution and were characterized by use of spectroscopic techniques, viz. MS-MS, FTIR, and NMR (1H, 13C and DEPT). On the basis of the spectral data, the structures 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 2-(4-(bis(pentyloxycarbonyl)amino)-5-fluoro-2-oxopyrimidin-(2H)-yl)-5-methyltetrahydrofuran-3,4-diyl diacetate were proposed for the three impurities.

Full access

predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis. 2002; 17: 46–49. 22 Leicher LW, Lammertink MH, Offerman SR, et al. Consequences of testing

Open access
Orvosi Hetilap
Authors: György Fogarassy, Ágnes Fogarassyné Vathy, Tamás Kováts, Lajos Hornyák, István Kenessey, Gábor Veress, Csaba Polgár, and Tamás Forster

cardiotoxicity: review of the literature. Cardiol J. 2012; 19: 453–458. 24 Endo A, Yoshida Y, Nakashima R, et al. Capecitabine induces both cardiomyopathy and

Open access

Sun, W., Haller, D. G., Mykulowszky, K. és mtsai: Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocallular carcinoma (HCC): a phase II study. J. Clin. Oncol., 2007, 25 , 4574

Open access

A Gorlin–Goltz-szindróma genetikai aspektusai

Genetic aspects of Gorlin‒Goltz syndrome

Orvosi Hetilap
Authors: Éva Vetró, Judit Oláh, Dóra Nagy, Márta Széll, József Piffkó, and László Seres

Beach DF, Somer R. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine. J Clin Oncol. 2011; 29: e397–e401. 23 Kesireddy M

Open access

Strosberg, J. R., Fine, R. L., Choi, J., et al.: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117 , 268–275. Choi J

Open access
Orvosi Hetilap
Authors: Richárd Szmola, Gyula Farkas, Péter Hegyi, László Czakó, Zsolt Dubravcsik, István Hritz, Dezső Kelemen, Natália Lásztity, Zita Morvay, Attila Oláh, Andrea Párniczky, Gábor Rubovszky, Miklós Sahin-Tóth, Zsolt Szentkereszti, Ákos Szücs, Tamás Takács, László Tiszlavicz, and Ákos Pap

., 2007, 25 (15), 1960–1966. Cunningham, D., Chau, I., Stocken, D. D., et al.: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin

Open access

–345. Fine, R. L., Gulati, A. P., Krantz, B. A., et al.: Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother. Pharmacol., 2013, 71 (3

Open access
Orvosi Hetilap
Authors: , Budapest, Üllői út 78., 1082, Csilla András, Péter Bartek, István Battyáni, János Bezsilla, György Bodoky, Barna Bogner, Attila Bursics, Tibor Csőszi, László Damjanovich, Magdolna Dank, Zsófia Dankovics, Pál Ákos Deák, Kristóf Dede, Attila Doros, Ibolyka Dudás, Tamás Györke, Oszkár Hahn, Erika Hartmann, Erika Hitre, Zsolt Horváth, Marianna Imre, Károly Kalmár Nagy, Zsolt Káposztás, László Kóbori, Péter Kupcsulik, László Landherr, Zoltán Lóderer, László Mangel, Zoltán Máthé, Tamás Mersich, Klára Mezei, Elemér Mohos, Attila Oláh, Péter Pajor, András Palkó, Zsuzsanna Pápai, András Papp, Mihály Patyánik, András Petri, János Révész, Ágnes Ruzsa, Krisztina Schlachter, László Sikorszki, István Sipőcz, Eszter Székely, Attila Szijártó, László Torday, Lajos Barna Tóth, Edit Dósa, László Harsányi, Gábor István, György Lázár, József Lövey, Zsuzsa Schaff, Ákos Szűcs, and András Vereczkei

Clin Oncol. 2008; 26: 4544–4550. 112 Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in

Open access
Orvosi Hetilap
Authors: Alexandra Bartal, Zoltán Mátrai, Attila Szűcs, Galina Belinszkaja, Zoltán Langmár, and András Rosta

Geyer, C. E., Forster, J., Lindquist, D., et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2006, 355 , 2733–2743. Lindquist D

Open access